We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis

By LabMedica International staff writers
Posted on 01 Oct 2026

Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells. More...

Despite their scarcity, CTCs can provide valuable information about cancer progression and treatment response, with concentrations sometimes as low as one to ten cells among a billion blood cells. 

Researchers at Taiyuan University of Technology and Shanxi Bethune Hospital developed the platform for CTC analysis. The system integrates inertial microfluidic enrichment with YOLOv8-based deep learning for bright-field image recognition. The approach is designed to enrich tumor cells in complex blood backgrounds without relying on specific cell-surface markers.

The microfluidic component uses a spiral chip containing engineered contraction-expansion structures. Because CTCs are generally larger than blood cells, different cell populations experience different forces as they move through the microchannel. The chip directs tumor cells and blood cells into separate flow paths, allowing tumor cells to be collected without antibody-based or marker-dependent capture.

The proof-of-concept study used artificial blood samples containing MCF-7 breast cancer cells and white blood cells. Tumor cells were enriched at the central outlet, while most blood cells were directed toward side outlets. The platform achieved an MCF-7 recovery rate of 89.2 ± 3.1% and a white blood cell removal rate of 86.9 ± 1.4%. The proportion of tumor cells increased from 9% before separation to 38% after enrichment.

For cell identification, the team used a YOLOv8 deep-learning model to recognize tumor cells from bright-field microscope images. Fluorescence images were used during model development to support annotation, but after training the model performed recognition using bright-field images alone. The model achieved 96.0% accuracy, 94.6% precision and recall, and 95.4% specificity in distinguishing tumor cells from non-tumor cells.

By combining microfluidic cell separation with AI-based image analysis, the platform targets two key challenges in CTC testing: isolating extremely rare tumor cells from complex blood samples and confirming their identity after enrichment. Because the workflow does not depend on labels or surface markers, it could streamline sample preparation while preserving cells for downstream uses such as single-cell sequencing and drug susceptibility testing. The findings also highlight the potential of pairing microfluidics with deep learning to expand rare-cell analysis.

The study was published in Biomedical Analysis under the title “Label-free Enrichment and Identification of Circulating Tumor Cells Integrating Inertial Microfluidics and Deep Learning.” The researchers described the work as a proof-of-concept study validated with MCF-7 cell lines and artificial blood samples rather than patient-derived specimens. The enrichment and recognition modules have also not yet been fully integrated into a single automated system. Future work will focus on additional tumor types, patient samples, system integration, and automation.

“The challenge of circulating tumor cell analysis is not only finding these rare cells, but also identifying them accurately after separation,” said Xiaochun Li, corresponding author from Taiyuan University of Technology. “By combining microfluidics with artificial intelligence, we hope to provide a simpler and more flexible approach for label-free CTC analysis and future downstream applications.”

Related Links
Taiyuan University of Technology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.